Drug intelligence / Profile preview

bevacizumab + tandutinib

Development stage: Phase 2
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Bevacizumab + tandutinib is a combination therapy that targets multiple aspects of tumor vasculature. Tandutinib (MLN518) is a piperazinyl quinazoline receptor tyrosine kinase inhibitor that inhibits the autophosphorylation of FLT3, c-KIT, and PDGF receptor tyrosine kinases. Bevacizumab is an anti-VEGF monoclonal antibody. The combination was investigated primarily for its potential to enhance antitumor activity by targeting both VEGF (via bevacizumab) and PDGFR/c-KIT (via tandutinib) pathways, capitalizing on the concept of targeting tumor vasculature through multiple mechanisms.

Targets

FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + tandutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + tandutinib.